Short Interest in MDxHealth SA (NASDAQ:MDXH) Declines By 76.8%

MDxHealth SA (NASDAQ:MDXH) saw a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 106,013 shares, a decline of 76.8% from the May 31st total of 457,830 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average trading volume of 796,277 shares, the short-interest ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. TD Cowen reaffirmed a “buy” rating and issued a $1.50 price target (down from $7.00) on shares of MDxHealth in a research note on Thursday, May 14th. Wall Street Zen downgraded MDxHealth from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. William Blair lowered shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th. Finally, BTIG Research lowered their target price on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $4.62.

Institutional Investors Weigh In On MDxHealth

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDXH. GSA Capital Partners LLP purchased a new position in MDxHealth during the third quarter valued at $48,000. Jefferies Financial Group Inc. purchased a new position in MDxHealth during the 3rd quarter valued at about $53,000. Russell Investments Group Ltd. bought a new stake in MDxHealth during the third quarter worth about $461,000. Kennedy Capital Management LLC purchased a new stake in MDxHealth in the third quarter worth about $1,826,000. Finally, FreeGulliver LLC increased its stake in shares of MDxHealth by 104.7% during the third quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock valued at $1,176,000 after purchasing an additional 129,348 shares in the last quarter.

MDxHealth Stock Performance

MDXH stock opened at $0.43 on Friday. MDxHealth has a 52 week low of $0.42 and a 52 week high of $5.33. The company has a market capitalization of $21.13 million, a PE ratio of -0.66 and a beta of 1.36. The company’s 50-day simple moving average is $1.17 and its 200 day simple moving average is $2.52.

MDxHealth (NASDAQ:MDXH) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $23.90 million for the quarter, compared to the consensus estimate of $30.89 million. MDxHealth had a negative net margin of 29.90% and a negative return on equity of 1,078.01%. On average, analysts forecast that MDxHealth will post -0.6 EPS for the current year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.